Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Mylan Defeats Allergan's Maneuver to Rent Tribal Sovereign Immunity to Avoid Restasis® Patent Cha…

  • Post author:Sam
  • Post published:February 25, 2018
  • Post category:BioPharma

U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge. Source: BioSpace

Continue ReadingMylan Defeats Allergan's Maneuver to Rent Tribal Sovereign Immunity to Avoid Restasis® Patent Cha…

TrueCare Biomedix Cited for Slew of Procedural Problems

  • Post author:Sam
  • Post published:February 23, 2018
  • Post category:Drug Industry Daily

The FDA slapped TrueCare Biomedix with a Form 483 for numerous procedural issues and violations observed during a November inspection of its facility in Gujarat, India. Source: Drug Industry Daily

Continue ReadingTrueCare Biomedix Cited for Slew of Procedural Problems

FDA Releases Finalized Q&A Guidance on Choosing Chemical Drug Starting Materials

  • Post author:Sam
  • Post published:February 23, 2018
  • Post category:Drug Industry Daily

The FDA finalized a Q&A guidance clarifying the International Council for Harmonization’s November 2012 Q11 guidance on development and manufacture of drug substances — giving recommendations for information that should…

Continue ReadingFDA Releases Finalized Q&A Guidance on Choosing Chemical Drug Starting Materials

Ex-Horizon Exec Claims Firing Was Retaliation for Whistleblowing at Previous Job

  • Post author:Sam
  • Post published:February 23, 2018
  • Post category:Drug Industry Daily

A former Horizon Pharma senior director sued the drugmaker, claiming she was fired for raising concerns about off-label drug promotion at a previous employer. Source: Drug Industry Daily

Continue ReadingEx-Horizon Exec Claims Firing Was Retaliation for Whistleblowing at Previous Job

CHMP Recommends Five Drugs, Including First Medicine for Neonatal Diabetes

  • Post author:Sam
  • Post published:February 23, 2018
  • Post category:Drug Industry Daily

The EMA’s Committee for Medicinal Products for Human Use recommended five medicines for European Commission approval and six extended indications at its meeting this month. Source: Drug Industry Daily

Continue ReadingCHMP Recommends Five Drugs, Including First Medicine for Neonatal Diabetes

EMA Recommends Short Physical Performance Battery for Assessing Frailty

  • Post author:Sam
  • Post published:February 23, 2018
  • Post category:Drug Industry Daily

The European Medicines Agency published a reflection paper on assessing the frailty of elderly patients in clinical trials, recommending the Short Physical Performance Battery assessment for its prognostic value and…

Continue ReadingEMA Recommends Short Physical Performance Battery for Assessing Frailty

Tax Reform Could Lead to Spike in Biopharma M&A Activity

  • Post author:Sam
  • Post published:February 22, 2018
  • Post category:BioPharma

The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Source: BioSpace

Continue ReadingTax Reform Could Lead to Spike in Biopharma M&A Activity

Women in Biotech Underrepresented on Boards of Directors Across the Bay Area

  • Post author:Sam
  • Post published:February 22, 2018
  • Post category:BioPharma

The proverbial glass ceiling for women in biotech has some cracks but it may not yet have shattered – particularly in the Bay Area hotbed. Source: BioSpace

Continue ReadingWomen in Biotech Underrepresented on Boards of Directors Across the Bay Area

3 Resume Tweaks to Help Scientists Get a Job in the Private Sector

  • Post author:Sam
  • Post published:February 22, 2018
  • Post category:BioPharma

According to the National Science Foundation (NSF), approximately 42% of life science professionals with doctorate degrees work in academia. Source: BioSpace

Continue Reading3 Resume Tweaks to Help Scientists Get a Job in the Private Sector

Teva's Shrinking U.S. Footprint

  • Post author:Sam
  • Post published:February 22, 2018
  • Post category:BioPharma

Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures. Source: BioSpace

Continue ReadingTeva's Shrinking U.S. Footprint
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 26
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company